Borchert G, Bartel S, Beyerdörfer I, Küttner I, Szekeres L, Krause E G
Max Delbrueck Centre for Molecular Medicine, Dept. Molecular Cardiology, Berlin-Buch, Germany.
Mol Cell Biochem. 1994 Mar 16;132(1):57-67. doi: 10.1007/BF00925675.
Evidence is accumulating that 7-oxo-prostacyclin (7-oxo-PGI2) induces a delayed indirect anti-adrenergic and cytoprotective effect on the myocardium, the mechanism of which is still unclear. To demonstrate that a single application of 7-oxo-PGI2 (50 micrograms/kg i.m.) 48 h prior to starting experiments attenuates the isoprenaline inducible inotropic response and accumulation of cAMP, isolated hearts of pretreated animals were perfused in the Langendorff mode with and without isoprenaline (1 to 100 nM). The late anti-adrenergic effect of the drug was manifested by a significant attenuation in the elevation of cAMP levels as well as in contractile force development. This effect was not due to changes in cAMP generation as there were identical beta 1-adrenoceptor densities and affinities (as calculated from [3H]-CGP binding studies), Gi and G alpha s protein patterns (as taken from Western blots) as well as adenylyl cyclase activity measurements in the hearts studied. The anti-adrenergic potency of 7-oxo-PGI2, however, was found to be related to a significant rise in cyclic nucleotide hydrolysis by phosphodiesterase (PDE). Using the fast-performance liquid chromatographic separation for PDE isoforms, a significant increase in the activity of PDE isoforms I and IV (260 +/- 28 vs 110 +/- 12 pmol cGMP/min x enzyme fraction and 77 +/- 11 vs 34 +/- 3 pmol cAMP/min x enzyme fraction, respectively) was found in the solubilized fraction of cardiac membranes in comparison to untreated controls; PDE IV activity was also increased in the cytosolic fraction (106 +/- 14 vs 65 +/- 6 pmol cAMP/min x enzyme fraction). The hypothesis that the delayed anti-adrenergic effect of 7-oxo-PGI2 is initiated by an induction and accelerated synthesis of PDE I and IV in the heart is underlined by the fact that cycloheximide suppresses completely both the rise in PDE activities and the anti-adrenergic effects studied. It is suggested that an inducible predominance of cAMP degradation over its generation may be of relevance in processes related to heart protection.
越来越多的证据表明,7-氧代前列环素(7-oxo-PGI2)对心肌具有延迟的间接抗肾上腺素能和细胞保护作用,但其机制仍不清楚。为了证明在开始实验前48小时单次注射7-氧代前列环素(50微克/千克,肌肉注射)可减弱异丙肾上腺素诱导的变力反应和环磷酸腺苷(cAMP)的积累,将预处理动物的离体心脏在Langendorff模式下进行灌注,分别加入和不加入异丙肾上腺素(1至100纳摩尔)。该药物的晚期抗肾上腺素能作用表现为cAMP水平升高以及收缩力发展的显著减弱。这种作用并非由于cAMP生成的变化,因为在所研究的心脏中,β1-肾上腺素能受体密度和亲和力(根据[3H]-CGP结合研究计算)、Gi和Gs蛋白模式(取自蛋白质免疫印迹)以及腺苷酸环化酶活性测量结果均相同。然而,发现7-氧代前列环素的抗肾上腺素能效力与磷酸二酯酶(PDE)引起的环核苷酸水解显著增加有关。使用快速高效液相色谱法分离PDE同工型,发现与未处理的对照组相比,心肌膜溶解部分中PDE同工型I和IV的活性显著增加(分别为260±28对110±12皮摩尔环鸟苷酸/分钟×酶组分和77±11对34±3皮摩尔cAMP/分钟×酶组分);PDE IV活性在胞质组分中也增加(106±14对65±6皮摩尔cAMP/分钟×酶组分)。环己酰亚胺完全抑制了PDE活性的升高和所研究的抗肾上腺素能作用,这一事实强调了7-氧代前列环素延迟的抗肾上腺素能作用是由心脏中PDE I和IV的诱导和加速合成引发的这一假设。有人提出,cAMP降解相对于其生成的诱导优势可能与心脏保护相关的过程有关。